Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy
ESC Heart Failure · 2025
DOI: 10.1002/ehf2.70014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2025. Verfasst von Carlos Moliner-Abós und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, Hospital de la Santa Creu i Sant Pau, CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Myocardial Ischemia, Myocardial Revascularization, Stroke Volume, Practice Guidelines as Topic. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministerio de Economía y Competitividad, Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, CIBERCV.
Abstract (Originalsprache)
Aims
Guideline-directed medical therapy (GDMT) remains the cornerstone for treating patients with heart failure (HF) and reduced ejection fraction (HFrEF) and coronary artery disease (CAD). However, real-world implementation of GDMT (GDMTi) is suboptimal. This subanalysis of the RevascHeart study evaluates the impact of GDMTi on long-term mortality in patients with de novo ischaemic heart failure (HF) undergoing revascularization.
Methods
Among 409 patients with HFrEF (left ventricular ejection fraction ≤40%) and CAD, 275 one-year survivors who underwent revascularisation shortly after index HF admission were included in this landmark analysis (LA). GDMTi at 12 months was defined as initiation of each recommended drug class, regardless of dose. Primary endpoints were all-cause and cardiovascular mortality by GDMTi. Secondary endpoints included outcomes by revascularisation strategy and temporal trends in GDMTi.
Results
Over a median follow-up of 41.6 months, all-cause mortality occurred in 29 GDMTi patients (18%) versus 47 non-GDMTi (42%) and cardiovascular mortality in 10% versus 24%, respectively. After adjustment, GDMTi was not significantly associated with lower all-cause [hazard ratio (HR) 0.63, 95% confidence interval (CI) 0.39–1.02; P = 0.06] or cardiovascular mortality (HR 0.62, 95% CI 0.33–1.18; P = 0.14). GDMTi/coronary artery bypass grafting (CABG) was associated with lower all-cause (HR 0.42, 95% CI 0.20–0.87; P = 0.02) and cardiovascular mortality (HR 0.40, 95% CI 0.16–0.99; P = 0.05). GDMTi use increased progressively over the study period.
Conclusions
GDMTi was associated with lower unadjusted mortality, though not significant after adjustment. GDMTi combined with CABG showed the best outcomes. The use of GDMTi improved over time.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cardiology Department, Hospital de la Santa Creu i Sant Pau, CIBERCV, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Cardiology Department, Hospital Universitari Dr. Josep Trueta, Girona, Spain.
- Institut de Recerca Sant Pau (IR SANTPAU), Barcelona, Spain.
- Institut d'Investigació Biomèdica de Girona (IDIBGI), Girona, Spain.
- Cardiology Department, Hospital Universitari Vall Hebrón, Barcelona, Spain.
- Cardiology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain.
ORCID-Profile: Carlos Moliner-Abós
Förderung
- Ministerio de Economía y Competitividad
- Instituto de Salud Carlos III
- Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares, CIBERCV
- European Regional Development Fund (ERDF)
Zitieren
APA
Moliner-Abós, C., Calvo-Barceló, M., Solé-Gonzalez, E., Borrellas Martín, A., Fluvià Brugués, P., Sánchez Vega, J., Vime Jubany, J., Ferré Vallverdú, M., Taurón Ferrer, M., Tobias Castillo, P. E., de la Fuente Mancera, J. C., Vilardell Rigau, P., Vila Olives, R., Diez López, C., Bayés-Genís, A., Arzamendi Aizpurua, D., Ferreira González, I., & Mirabet Pérez, S. (2025). Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy. ESC Heart Failure. https://doi.org/10.1002/ehf2.70014
Vancouver
Moliner-Abós C, Calvo-Barceló M, Solé-Gonzalez E, Borrellas Martín A, Fluvià Brugués P, Sánchez Vega J, et al. Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy. ESC Heart Failure. 2025. doi:10.1002/ehf2.70014
BibTeX
@article{MolinerAbs2025,
author = {Moliner-Abós, Carlos and Calvo-Barceló, Maria and Solé-Gonzalez, Eduard and Borrellas Martín, Andrea and Fluvià Brugués, Paula and Sánchez Vega, Jesus and Vime Jubany, Joan and Ferré Vallverdú, Maria and Taurón Ferrer, Manel and Tobias Castillo, Pablo Eduardo and de la Fuente Mancera, Juan Carlos and Vilardell Rigau, Pau and Vila Olives, Rosa and Diez López, Carles and Bayés-Genís, Antoni and Arzamendi Aizpurua, Dabit and Ferreira González, Ignacio and Mirabet Pérez, Sònia},
title = {Guideline-Directed Medical Therapy After Revascularization and Outcomes in Ischaemic Cardiomyopathy},
journal = {ESC Heart Failure},
year = {2025},
doi = {10.1002/ehf2.70014}
}
EUVIMED